Connect with us

U.S. Supreme Court

Supreme Court to consider challenge to Tenn. law challenging gender-affirming case for minors

Volunteer State lawmakers approved ban in 2023

Published

on

U.S. Supreme Court (Washington Blade photo by Michael Key)

The U.S. Supreme Court on Monday agreed to consider a challenge to a Tennessee law that bans health care providers from offering gender-affirming care to transgender minors.

Tennessee lawmakers approved the law in 2023.

A federal judge in Nashville issued a temporary injunction against portions of the statute before it was to have taken effect on July 1, 2023. The 6th U.S. U.S. Circuit Court of Appeals last September rejected a request to block the law the Justice Department has also challenged.

ā€œThe future of countless transgender youth in this and future generations rests on this court adhering to the facts, the Constitution, and its own modern precedent,ā€ said Chase Strangio, deputy director for transgender justice at the American Civil Liberties Union’s LGBTQ and HIV Project, on Monday in a press release. “These bans represent a dangerous and discriminatory affront to the well-being of transgender youth across the country and their constitutional right to equal protection under the law. They are the result of an openly political effort to wage war on a marginalized group and our most fundamental freedoms.”Ā 

“We want transgender people and their families across the country to know we will spare nothing in our defense of you, your loved ones, and your right to decide whether to get this medical care,ā€ added Strangio.

The Associated Press reported Tennessee is among the more than two dozen states that have enacted laws that either restrict or ban gender-affirming care for trans minors.

The ACLU notes the Supreme Court “is not expected to hear arguments” in the case until the fall.

Advertisement
FUND LGBTQ JOURNALISM
SIGN UP FOR E-BLAST

U.S. Supreme Court

Supreme Court rules to preserve access to abortion medication

Case is Alliance for Hippocratic Medicine v. FDA

Published

on

The abortifacent drug mifepristone is marketed under the brand name Mifeprex (Photo courtesy of Danco Laboratories)

The U.S. Supreme Court ruled Thursday in a much-anticipated decision against efforts by conservative doctors and medical groups challenging access to mifepristone, one of two pharmaceuticals used in medication abortions. As a result of the high court’s decision, access to the drug wonā€™t change.

Associate Supreme Court Justice Brett Kavanaugh, writing for the court, reversed a lower court decision that would have made it more difficult to obtain the drug, which is used in about two-thirds of U.S. abortions. The ruling however was narrow in scope as it only addressed what is known as legal standing in a case.

SCOTUSblog senior court reporter Amy Howe noted that Kavanaugh acknowledged what he characterized as the challengersā€™ ā€œsincere legal, moral, ideological, and policy objectionsā€ to elective abortion ā€œby othersā€ and to FDAā€™s 2016 and 2021 changes to the conditions on the use of the drug.

But the challengers had not shown that they would be harmed by the FDAā€™s mifepristone policies, he explained, and under the Constitution, merely objecting to abortion and the FDAā€™s policies are not enough to bring a case in federal court. The proper place to voice those objections, he suggested, is in the political or regulatory arena.

ā€œUnder Article III of the Constitution, a plaintiffā€™s desire to make a drug less available for others does not establish standing to sue,ā€ Kavanaugh wrote.

ā€œWe are pleased with the Supreme Courtā€™s decision in this incredibly important case. By rejecting the Fifth Circuitā€™s radical, unprecedented and unsupportable interpretation of who has standing to sue, the justices reaffirmed longstanding basic principles of administrative law,ā€ said Abigail Long, a spokesperson for Danco. ā€œThe decision also safeguards access to a drug that has decades of safe and effective use.ā€

The White House released a statement from President Joe Biden on Supreme Court Decision on FDA v. Alliance for Hippocratic Medicine:

“Todayā€™s decision does not change the fact that the fight for reproductive freedom continues. It does not change the fact that the Supreme Court overturned Roe v. Wade two years ago, and women lost a fundamental freedom. It does not change the fact that the right for a woman to get the treatment she needs is imperiled if not impossible in many states.
 
It does mean that mifepristone, or medication abortion, remains available and approved. Women can continue to access this medication – approved by the FDA as safe and effective more than 20 years ago. 
 
But letā€™s be clear: attacks on medication abortion are part of Republican elected officialsā€™ extreme and dangerous agenda to ban abortion nationwide. Since the overturning of Roe v. Wade, Republican elected officials have imposed extreme abortion bans in 21 states, some of which include zero exceptions for rape or incest. Women are being turned away from emergency rooms, or forced to go to court to plead for care that their doctor recommended or to travel hundreds of miles for care. Doctors and nurses are being threatened with jail time, including life in prison, for providing the health care they have been trained to provide. And contraception and IVF are under attack.
 
The stakes could not be higher for women across America. Vice President Harris and I stand with the vast majority of Americans who support a womanā€™s right to make deeply personal health care decisions. We will continue to fight to ensure that women in every state get the health care they need and we will continue to call on Congress to restore the protections of Roe v. Wade in federal law ā€” that is our commitment.”

U.S. District Court for the Northern District of Texas Judge Matthew Kacsmaryk in Amarillo, Texas, in a ruling a year ago, waved aside decades of scientific approval, ruled that the U.S. Food and Drug Administration improperly approved mifepristone more than 20 years ago in 2000.

Kacsmaryk, appointed to the federal bench by former President Donald Trump, in his 67 page opinion wrote that the FDAā€™s two-decade-old approval violated a federal rule that allows for accelerated approval for certain drugs and, along with subsequent actions by the agency, was unlawful.

The suit, Alliance for Hippocratic Medicine v. FDA, was originally filed in the U.S. District Court for the North District of Texas in mid-November by Alliance Defending Freedom, an anti-abortion, anti-LGBTQ+ legal organization.

Applauding Kacsmarykā€™s ruling, Erik Baptist, speaking for the Alliance Defending Freedom said in a statement: ā€œBy illegally approving dangerous chemical abortion drugs, the FDA put women and girls in harmā€™s way, and itā€™s high time the agency is held accountable for its reckless actions.ā€

Erin Hawley, a senior attorney for the conservative group Alliance Defending Freedom who argued the case at the Supreme Court, said the opinion was ā€œdisappointing,ā€ but told reporters in a press gaggle after the ruling that the explicit mention of conscience protections was a victory.

ā€œThe Supreme Court was crystal clear that pro life doctors do have federal conscience protections, even in emergency situations,ā€ Hawley said. ā€œSo thatā€™s a huge win for the pro-life cause. The Supreme Court clearly said that our doctors are entitled to those federal conscious protections that are based on their religious beliefs.ā€

The case now returns to the lower courts, and the dispute over access to the drug likely is not over.Ā 

SCOTUSblog also reported that Nancy Northrup, the president and CEO of the Center for Reproductive Rights, praised the decision but conceded that the dispute could continue even after Thursdayā€™s ruling. She, too, noted that the three states ā€œcould still attempt to keep the case going, including taking it back up to the Supreme Court,ā€ and she warned that access to mifepristone ā€œis still at risk nationwide.ā€

The Hill notes that for instance, the same district court in Texas that originally ruled against the FDA said a group of three red statesā€”Missouri, Idaho and Kansasā€” can intervene in the lawsuit.

ā€œI would expect the litigation to continue with those states raising different standing arguments than made by our doctors,ā€ ADF’s Hawley told reporters.

Equality California, the nationā€™s largest statewide LGBTQ+ civil rights organization, emailed the Blade the following statement from Executive Director Tony Hoang in response to a unanimous ruling by the United States Supreme Court:

ā€œWe appreciate today’s unanimous decision to uphold access to the abortion drug mifepristone, authored by a conservative Justice. This ruling reinforces the critical importance of maintaining accessible reproductive healthcare and highlights the necessity of safeguarding these rights from baseless legal attacks.

However, it is imperative to recognize that the Court should never have accepted this case. The so-called Alliance for Hippocratic Medicine lacked the standing to initiate this challenge. Moreover, federal conscience exemptions already exist for healthcare providers who object to offering abortion-related care. 

Medication abortions involving mifepristone constitute the majority of abortions in America, including those sought by LGBTQ+ people. Our community understands the necessity of bodily autonomy and the right to make decisions regarding our own medical care, including reproductive care. Patients deserve access to the medications they need, and providers should be able to deliver that care without unwarranted interference from extremist courts or politicians.   

Attacks on abortion do not end with this decision; millions of people nationwide are still unable to get abortion care and abortion opponents remain focused on their end goal of a nationwide abortion ban. 

Equality California will continue to work with our legislative partners in Sacramento and Washington, D.C., as well as organizational allies, like Planned Parenthood, to help protect and expand access to abortion and reproductive healthcare.ā€

Continue Reading

U.S. Supreme Court

Supreme Court declines to hear lawsuit against Montgomery County schools gender guidelines

4th Circuit last August dismissed parents’ case

Published

on

U.S. Supreme Court (Washington Blade photo by Michael Key)

The U.S. Supreme Court on Monday declined to hear a lawsuit against Montgomery County Public Schools guidelines that allow schools to create plans in support of transgender or gender nonconfirming students without their parents’ knowledge or consent.

Three parents of students in the school district ā€” none of whom have trans or gender nonconfirming children ā€” filed the lawsuit. 

A judge on the 4th U.S. Circuit Court of Appeals last August dismissed the case. The plaintiffs appealed the decision to the Supreme Court.

Continue Reading

U.S. Supreme Court

US Supreme Court rules Idaho to enforce gender care ban

House Bill 71 signed in 2023

Published

on

U.S. Supreme Court (Washington Blade photo by Michael Key)

BY MIA MALDONADO | The U.S. Supreme Court has allowed Idaho to enforce House Bill 71, a law banning Idaho youth from receiving gender-affirming care medications and surgeries.

In an opinion issued Monday, the U.S. Supreme Court granted the state of Idahoā€™s request to stay the preliminary injunction, which blocked the law from taking effect. This means the preliminary injunction now only applies to the plaintiffs involved in Poe v. Labrador ā€” a lawsuit brought on by the families of two transgender teens in Idaho who seek gender-affirming care. 

Mondayā€™s Supreme Court decision enforces the gender-affirming care ban for all other trans youth in Idaho as the lawsuitĀ remains ongoing in the Ninth Circuit Court of Appeals.

Idaho Attorney General RaĆŗl Labrador
Idaho Attorney General RaĆŗl Labrador gives a speech at the Idaho GOP election night watch party at the Grove Hotel in Boise, Idaho, on Nov. 8, 2022. (Otto Kitsinger for Idaho Capital Sun)

The American Civil Liberties Union and the ACLU of Idaho, both of whom represent the plaintiffs, said in a press release Monday that the ruling ā€œdoes not touch upon the constitutionalityā€ of HB 71. The groups called Mondayā€™s ruling an ā€œawful resultā€ for trans Idaho youth and their families.

ā€œTodayā€™s ruling allows the state to shut down the care that thousands of families rely on while sowing further confusion and disruption,ā€ the organizations said in the press release. ā€œNonetheless, todayā€™s result only leaves us all the more determined to defeat this law in the courts entirely, making Idaho a safer state to raise every family.ā€

Idaho Attorney General RaĆŗl Labrador in a press release said the state has a duty to protect and support all children, and that he is proud of the stateā€™s legal stance. 

ā€œThose suffering from gender dysphoria deserve love, support and medical care rooted in biological reality,ā€ Labrador said. ā€œDenying the basic truth that boys and girls are biologically different hurts our kids. No one has the right to harm children, and Iā€™m grateful that we, as the state, have the power ā€” and duty ā€” to protect them.ā€

Recap of Idahoā€™s HB 71, and what led to SCOTUS opinion

Mondayā€™s Supreme Court decision traces back to when HB 71 was signed into law in April 2023.

The law makes it a felony punishable for up to 10 years for doctors to provide surgeries, puberty-blockers and hormones to trans people under the age of 18. However, gender-affirming surgeries are not and were not performed among Idaho adults or youth before the bill was signed into law, the Idaho Capital Sun previously reported

One month afterĀ it was signed into law, the families of two trans teens sued the state in a lawsuit alleging the bill violates the 14th Amendmentā€™s guarantee of equal protection under the law.

In late December, just days before the law was set to take effect in the new year, U.S. District Judge B. Lynn Winmill blocked the law from taking effect under a preliminary injunction. In his decision, he said he found the families likely to succeed in their challenge.

The state of Idaho responded by appealing the district courtā€™s preliminary injunction decision to the Ninth Circuit, to which the Ninth Circuit denied. The state of Idaho argued the court should at least enforce the ban for everyone except for the plaintiffs. 

After the Ninth Circuitā€™s denial, the Idaho Attorney Generalā€™s Office in February sent an emergency motion to the U.S. Supreme Court, the Idaho Press reported. Mondayā€™s U.S. Supreme Court decision agrees with the stateā€™s request to enforce its ban on trans health care for minors, except for the two plaintiffs.

******************************************************************************************

Mia Maldonado

Mia Maldonado joined the Idaho Capital Sun after working as a breaking news reporter at the Idaho Statesman covering stories related to crime, education, growth and politics. She previously interned at the Idaho Capital Sun through the Voces Internship of Idaho, an equity-driven program for young Latinos to work in Idaho news. Born and raised in Coeur d’Alene, Mia moved to the Treasure Valley for college where she graduated from the College of Idaho with a bachelor’s degree in Spanish and international political economy.

******************************************************************************************

The preceding piece was previously published by the Idaho Capital Sun and is republished with permission.

The Idaho Capital Sun is the Gem Stateā€™s newest nonprofit news organization delivering accountability journalism on state politics, health care, tax policy, the environment and more.

Weā€™re part of States Newsroom, the nationā€™s largest state-focused nonprofit news organization.

Continue Reading
Advertisement
Advertisement

Sign Up for Weekly E-Blast

Follow Us @washblade

Advertisement

Popular